ARENA PHARMACEUTICALS INC
ARNA evidence brief
What we can confirm
- BioSniper Score:
- 8.5 / 10
- Lead Asset:
- apd418 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for ARNA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
apd418 (Phase 2)
Next Catalyst
—
Tracking 5 pipeline candidates for ARENA PHARMACEUTICALS INC.
Run ARENA PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ARENA PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is ARENA PHARMACEUTICALS INC's lead drug candidate?
ARENA PHARMACEUTICALS INC's most advanced tracked candidate is apd418 (Phase 2) for acute heart failure.
Who is the CEO of ARENA PHARMACEUTICALS INC?
Arena Pharmaceuticals is the chief executive officer of ARENA PHARMACEUTICALS INC (ARNA).
What therapeutic areas does ARENA PHARMACEUTICALS INC focus on?
ARENA PHARMACEUTICALS INC develops therapies across Cardiovascular, Respiratory, Pain, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.